TNYA

Tenaya Therapeutics Inc

TNYA, USA

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

https://www.tenayatherapeutics.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
TNYA
stock
TNYA

Tenaya Therapeutics (TNYA) Is Down 39.7% After Cardiac Gene Therapy Milestones And $60M Fundraise - What's Changed Yahoo Finance

Read more →
TNYA
stock
TNYA

Tenaya Therapeutics (NASDAQ:TNYA) Given New $3.00 Price Target at HC Wainwright MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$10.1429

Analyst Picks

Strong Buy

6

Buy

3

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Low

1.68

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-24.47 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-19.31 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.27

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 21.57% of the total shares of Tenaya Therapeutics Inc

1.

Column Group LLC

(5.7679%)

since

2025/06/30

2.

Vanguard Group Inc

(2.9178%)

since

2025/06/30

3.

Vanguard Total Stock Mkt Idx Inv

(1.7293%)

since

2025/07/31

4.

BlackRock Inc

(1.6768%)

since

2025/06/30

5.

Renaissance Technologies Corp

(1.1314%)

since

2025/06/30

6.

AQR Capital Management LLC

(1.069%)

since

2025/06/30

7.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7572%)

since

2025/07/31

8.

Geode Capital Management, LLC

(0.7551%)

since

2025/06/30

9.

Euclidean Capital LLC

(0.6232%)

since

2025/06/30

10.

Alphabet Inc

(0.5619%)

since

2025/06/30

11.

Millennium Management LLC

(0.4177%)

since

2025/06/30

12.

Aberdeen Group PLC

(0.3686%)

since

2025/06/30

13.

abrdn Life Sciences Investors

(0.3686%)

since

2025/08/31

14.

Fidelity Extended Market Index

(0.3359%)

since

2025/07/31

15.

Two Sigma Investments LLC

(0.2913%)

since

2025/06/30

16.

StepStone Group LLC

(0.2836%)

since

2025/06/30

17.

Squarepoint Ops LLC

(0.2355%)

since

2025/06/30

18.

Jane Street Group LLC

(0.2308%)

since

2025/06/30

19.

Casdin Capital, LLC

(0.2221%)

since

2025/06/30

20.

Susquehanna International Group, LLP

(0.1895%)

since

2025/06/30

21.

Royal Bank of Canada

(0.1806%)

since

2025/06/30

23.

Goldman Sachs Group Inc

(0.1719%)

since

2025/06/30

24.

Vifag 2002 SICAV

(0.1534%)

since

2025/07/31

25.

State Street Corp

(0.1287%)

since

2025/06/30

26.

Fidelity Total Market Index

(0.1078%)

since

2025/07/31

27.

Fidelity Nasdaq Composite Index

(0.0959%)

since

2025/07/31

28.

Fidelity Series Total Market Index

(0.0912%)

since

2025/07/31

29.

Galileo - Biotech Innovation Fund S USD

(0.0791%)

since

2025/02/28

30.

Spartan Extended Market Index Pool F

(0.0737%)

since

2025/07/31

31.

Extended Equity Market Fund K

(0.0671%)

since

2025/06/30

32.

Spartan Total Market Index Pool G

(0.0504%)

since

2025/07/31

33.

NT Ext Equity Mkt Idx Fd - L

(0.0392%)

since

2025/06/30

34.

Northern Trust Extended Eq Market Idx

(0.0392%)

since

2025/06/30

35.

Vanguard Balanced Index Inv

(0.0359%)

since

2025/07/31

36.

Goldman Sachs Absolute Ret Trckr Instl

(0.0341%)

since

2025/06/30

37.

NT Ext Equity Mkt Idx Fd - NL

(0.0293%)

since

2025/06/30

38.

AST Small Cap Value

(0.0282%)

since

2024/11/30

39.

NT Col R2000 Val Idx Fd -DC -L -TierFour

(0.0272%)

since

2025/03/31

40.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.026%)

since

2024/12/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.1442

Latest Release

Date

2025-09-30

EPS Actual

-0.12

EPS Estimate

-0.15

EPS Difference

0.03

Surprise Percent

20%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.

Tenaya Therapeutics Inc (TNYA) Stock Details & Analysis - Finnton | Finnton